drugset / Trial / NCT00470665

Study Comparing Sirolimus/Prograf vs Sirolimus/CsA in High-Risk Renal Transplant Recipients

NCT00470665

Phase 3 Completed 460 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to assess whether in high-risk kidney transplant patients (patients whose previous kidney transplant failed, have a high PRA lab test result or are of African-American descent) that a combination of Rapamune with Prograf and steroids will prevent acute rejection as well as Rapamune and cyclosporine and steroids.

Timeline

Start
2002-08
Primary completion
Completion
2004-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule

Indications

No indication recorded.